Clinical Research Directory

Inclusion Criteria: 1. \- Type 2 DM. 2. \- HbA1c \> 53 mmol/l (7.0 %, estimated average glucose (eAG) 8.6 mmol/l). 3. \- Contact to diabetes clinic for ≥ 6 months. 4. \- Insulin treatment ≥ 12 months. 5. \- Basal insulin and bolus insulin at least for one meal every day. 6. \- Bolus insulin is insulin aspart. 7. \- Stable insulin treatment (change 10 % or less) and no introduction of other antihyperglycemic agents (oral or GLP1 analogue) for at least 2 months before randomization. 8. \- Considered to be technically and intellectually capable of using isCGM and smart pen. 9. \- Can communicate in Danish. 10. \- Informed consent including acceptance to share glucose data from the Libreview platforms. 11. \- The patient has a smart phone suitable for Libre and NOVOpen6 data registration. Exclusion Criteria: 1. \- Individual goal for HbA1c is reached (even if \> 53 mmol/mol), i.e. relaxed treatment goals as relevant for fragile patients with severe diabetic complications or comorbidities. 2. \- Fasting C-peptide \< 370 pmol/l. 3. \- Actual treatment with CGM or previous use of CGM for more than four weeks or \< 6 months before recruitment. No actual or previous use of connected pen. 4. \- One or more severe hypoglycemic episode (assistance of third party) within the previous 12 months. 5. \- Considered unable to participate due to frequent cancellation of appointments. 6. \- Ongoing steroid treatment or expected intermittent treatment of more than 14 days' duration. 7. \- Pregnant or planning pregnancy. 8. \- Participating in other trials. 9. \- Clinical conditions interfering with interpretation of HbA1c (phlebectomy, bleeding or haemolytic disorders, erythropoietin treatment, known haemoglobin variants, etc.) or continuous intake of high dose of vitamin C (\> 1000 mg), salicylic acid (650 mg daily), Salazopyrin or Dapsone. 10. \- Allergic reaction to the adhesive used in the isCGM.